These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 7573867)
81. Dose response, recovery, and cost of doxacurium as a continuous infusion in neurosurgical intensive care unit patients. Prielipp RC; Robinson JC; Wilson JA; MacGregor DA; Scuderi PE Crit Care Med; 1997 Jul; 25(7):1236-41. PubMed ID: 9233753 [TBL] [Abstract][Full Text] [Related]
82. [Potentiation of nondepolarizing muscle relaxants by nifedipine iv in inhalation anesthesia]. Jelen-Esselborn S; Blobner M Anaesthesist; 1990 Mar; 39(3):173-8. PubMed ID: 1970460 [TBL] [Abstract][Full Text] [Related]
83. Edrophonium as an antagonist of vecuronium-induced neuromuscular block in the elderly. Kitajima T; Ishii K; Ogata H Anaesthesia; 1995 Apr; 50(4):359-61. PubMed ID: 7747859 [TBL] [Abstract][Full Text] [Related]
84. Comparison of the effects of mivacurium on the diaphragm and geniohyoid muscles. d'Honneur G; Slavov V; Merle JC; Kirov K; Rimaniol JM; Sperry L; Duvaldestin P Br J Anaesth; 1996 Dec; 77(6):716-9. PubMed ID: 9014621 [TBL] [Abstract][Full Text] [Related]
85. Potency of doxacurium in infants, children, and adolescents during N2O-O2-alfentanil anesthesia. Taivainen TR; Meretoja OA J Clin Anesth; 1996 May; 8(3):225-8. PubMed ID: 8703459 [TBL] [Abstract][Full Text] [Related]
86. Recovery from doxacurium infusion administered to produce immobility for more than four days in pediatric patients in the intensive care unit. Brandom BW; Yellon RF; Lloyd ME; Gronert BJ; Theroux MC; Simhi E; Chakravorti S; Venkataraman S; Dohar JE; Shapiro AM; Rimell FL; Reilly JS Anesth Analg; 1997 Feb; 84(2):307-14. PubMed ID: 9024019 [TBL] [Abstract][Full Text] [Related]
87. Pharmacokinetic-pharmacodynamic modeling of doxacurium: effect of input rate. Zhu Y; Audibert G; Donati F; Varin F J Pharmacokinet Biopharm; 1997 Feb; 25(1):23-37. PubMed ID: 9353692 [TBL] [Abstract][Full Text] [Related]
88. The influence of renal function on the pharmacokinetics and pharmacodynamics and simulated time course of doxacurium. Fisher DM; Reynolds KS; Schmith VD; Hsu J; Sokoll MD; Lennon RL; Caldwell JE Anesth Analg; 1999 Sep; 89(3):786-95. PubMed ID: 10475326 [TBL] [Abstract][Full Text] [Related]
93. Reversal of doxacurium and pancuronium neuromuscular blockade with neostigmine in children. Bevan JC; Purday JP; Reimer EJ; Bevan DR Can J Anaesth; 1994 Nov; 41(11):1074-80. PubMed ID: 7828255 [TBL] [Abstract][Full Text] [Related]
94. Dose-response relations of doxacurium and its reversal with neostigmine in young adults and healthy elderly patients. Koscielniak-Nielsen ZJ; Law-Min JC; Donati F; Bevan DR; Clement P; Wise R Anesth Analg; 1992 Jun; 74(6):845-50. PubMed ID: 1534472 [TBL] [Abstract][Full Text] [Related]
95. The clinical pharmacology of doxacurium in young adults and in elderly patients. Martlew RA; Harper NJ Anaesthesia; 1995 Sep; 50(9):779-82. PubMed ID: 7573867 [TBL] [Abstract][Full Text] [Related]